for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

JCRファーマ株式会社

4552.T

現在値

3,060.00JPY

変化

62.00(+2.07%)

出来高

310,100

本日のレンジ

2,970.00

 - 

3,060.00

52週レンジ

2,336.00

 - 

3,800.00

∙ 約20分前の相場を表示しています。

適時開示

Mesoblast And JCR Pharmaceuticals Expand Japan License Agreement

June 11 (Reuters) - JCR Pharmaceuticals Co Ltd <4552.T>::MESOBLAST AND JCR PHARMACEUTICALS EXPAND JAPAN LICENSE AGREEMENT TO USE OF MESENCHYMAL STEM CELLS IN NEWBORNS WITH INSUFFICIENT BLOOD FLOW TO THE BRAIN.MESOBLAST LTD - EXPANDED ITS PARTNERSHIP WITH JCR PHARMACEUTICALS CO. LTD. IN JAPAN.MESOBLAST LTD - DEAL FOR USE OF MESENCHYMAL STEM CELLS (MSCS) FOR TREATMENT OF NEWBORNS WHO LACK SUFFICIENT BLOOD SUPPLY AND OXYGEN TO BRAIN.MESOBLAST LTD - DEAL FOR AGREEMENT HAS NOW BEEN FURTHER EXPANDED TO PROVIDE JCR WITH RIGHTS TO SELL TEMCELL FOR HIE.MESOBLAST LTD - DEAL FOR JCR PLANS TO INITIATE A CLINICAL TRIAL OF TEMCELL IN NEWBORNS WITH HIE IN JULY 2019.

Mesoblast Expands Partnership With JCR Pharmaceuticals In Japan

June 11 (Reuters) - Mesoblast Ltd <MSB.AX>::MESOBLAST LTD - AGREEMENT HAS NOW BEEN FURTHER EXPANDED TO PROVIDE JCR WITH RIGHTS TO SELL TEMCELL FOR HIE .MESOBLAST LTD - JCR PLANS TO INITIATE A CLINICAL TRIAL OF TEMCELL IN NEWBORNS WITH HIE IN JULY 2019 .MESOBLAST AND JCR PHARMACEUTICALS EXPAND JAPAN LICENSE AGREEMENT TO USE OF MESENCHYMAL STEM CELLS IN NEWBORNS WITH INSUFFICIENT BLOOD FLOW TO THE BRAIN.MESOBLAST LTD - EXPANDED ITS PARTNERSHIP WITH JCR PHARMACEUTICALS CO. LTD. IN JAPAN.MESOBLAST LTD - DEAL FOR USE OF MESENCHYMAL STEM CELLS (MSCS) FOR TREATMENT OF NEWBORNS WHO LACK SUFFICIENT BLOOD SUPPLY AND OXYGEN TO BRAIN.

Mesoblast Expands Partnership With JCR Pharmaceuticals

Oct 24 (Reuters) - Mesoblast Ltd <MSB.AX>::EXPANDS PARTNERSHIP WITH JCR PHARMACEUTICALS FOR TREATMENT OF WOUND HEALING IN EPIDERMOLYSIS BULLOSA.

JCR Pharmaceuticals initiates phase 3 clinical trial of JR-141 for Hunter Syndrome

Aug 9 (Reuters) - JCR Pharmaceuticals Co Ltd <4552.T>:Says the company announced today the initiation of a Phase 3 clinical trial of JR-141 in Japan .JR-141 is a blood-brain-barrier (BBB)-penetrating recombinant iduronate-2-sulfatase product candidate for the treatment of patients with Hunter syndrome, to which J-Brain Cargo®, JCR’s proprietary BBB technology, is applied .

JCR Pharmaceuticals initiates phase 2 clinical trial of JR-141 for hunter syndrome in Brazil

June 29 (Reuters) - JCR Pharmaceuticals Co Ltd <4552.T>:Says it announced today the initiation of the Phase 2 clinical trial of JR-141 in Brazil.JR-141 is a blood-brain-barrier(BBB)-penetrating recombinant iduronate-2-sulfatase product candidate for the treatment of patients with Hunter syndrome, to which J-Brain Cargo®, JCR's proprietary BBB technology, has been applied .

JCR Pharmaceuticals to recall partial sleep apnea alarm products

June 25 (Reuters) - JCR Pharmaceuticals Co Ltd <4552.T> ::Says it plans to recall its partial sleep apnea alarm products, which are manufactured by the company and sold by the company and its unit, due to parts' quality problem .

JCR Pharmaceuticals to set up investigational new drug production center with investment of 3 bln yen

April 26 (Reuters) - JCR Pharmaceuticals Co Ltd <4552.T>:Says it will set up an investigational new drug production center with investment of about 3 billion yen from March 2019 .

JR-131, long-acting erythropoiesis-stimulating agent, demonstrates equivalence in phase III study

Jan 17 (Reuters) - Kissei Pharmaceutical Co Ltd <4547.T>:Says it and JCR Pharmaceuticals Co Ltd <<<4552.T>>> jointly announced positive results of the phase III study for JR-131, a proposed biosimilar to darbepoetin alfa, a long-acting erythropoiesis-stimulating agent for the treatment of renal anemia .In the Phase III study initiated in August 2016, JR-131 demonstrated equivalence in efficacy and safety compared with darbepoetin.Accordingly, in a primary endpoint of efficacy, the equivalence was verified for variations in hemoglobin concentration and the similarity with regard to the safety profile was confirmed .

Medipal Holdings signs contract to set up JV JCR USA with JCR Pharmaceuticals

Dec 19(Reuters) - Medipal Holdings Corp <7459.T>:Says it signed a contract to set up a JV JCR USA Inc with JCR Pharmaceuticals Co Ltd <<<4552.T>>>.Says the JV will be established in January 2018.Says the company and JCR Pharmaceuticals will hold a 35 percent stake and a 65 percent stake in the JV respectively .

JCR Pharmaceuticals to initiate development of JR-171, new drug candidate for Hurler Syndrome using J-Brain Cargo

Oct 26 (Reuters) - JCR Pharmaceuticals Co Ltd <4552.T>:Says it will initiate development of JR-171, new drug candidate for Hurler Syndrome using J-Brain Cargo.

金融情報はリフィニティブから。すべての情報は少なくとも20分遅れで表示されています。

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up